Last reviewed · How we verify

ACE inhibitors

GlaxoSmithKline · FDA-approved active Small molecule ✓ Verified Jun 2026

ACE inhibitors is a ACE inhibitor Small molecule drug developed by GlaxoSmithKline. It is currently FDA-approved for Hypertension, Heart failure with reduced ejection fraction, Post-myocardial infarction. Also known as: Beta-blockers including Carvedilol, Lisinopril, Captopril, angiotensin-converting-enzyme inhibitor.

ACE inhibitors block the angiotensin-converting enzyme, preventing the conversion of angiotensin I to angiotensin II and thereby reducing vasoconstriction and aldosterone release.

ACE inhibitors are a class of medication primarily used for the treatment of high blood pressure and heart failure. They work by causing relaxation of blood vessels and a decrease in blood volume, leading to lower blood pressure and decreased oxygen demand from the heart.

At a glance

Generic nameACE inhibitors
Also known asBeta-blockers including Carvedilol, Lisinopril, Captopril, angiotensin-converting-enzyme inhibitor
SponsorGlaxoSmithKline
Drug classACE inhibitor
TargetAngiotensin-converting enzyme (ACE)
ModalitySmall molecule
Therapeutic areaCardiovascular
PhaseFDA-approved

Mechanism of action

By inhibiting ACE, these drugs lower levels of angiotensin II, a potent vasoconstrictor and hormone that increases blood pressure and promotes sodium retention. This leads to vasodilation, reduced blood pressure, decreased cardiac workload, and improved renal perfusion. The mechanism also reduces cardiac remodeling and fibrosis, making ACE inhibitors beneficial in heart failure and post-myocardial infarction settings.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about ACE inhibitors

What is ACE inhibitors?

ACE inhibitors is a ACE inhibitor drug developed by GlaxoSmithKline, indicated for Hypertension, Heart failure with reduced ejection fraction, Post-myocardial infarction.

How does ACE inhibitors work?

ACE inhibitors block the angiotensin-converting enzyme, preventing the conversion of angiotensin I to angiotensin II and thereby reducing vasoconstriction and aldosterone release.

What is ACE inhibitors used for?

ACE inhibitors is indicated for Hypertension, Heart failure with reduced ejection fraction, Post-myocardial infarction, Diabetic nephropathy, Chronic kidney disease.

Who makes ACE inhibitors?

ACE inhibitors is developed and marketed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).

Is ACE inhibitors also known as anything else?

ACE inhibitors is also known as Beta-blockers including Carvedilol, Lisinopril, Captopril, angiotensin-converting-enzyme inhibitor.

What drug class is ACE inhibitors in?

ACE inhibitors belongs to the ACE inhibitor class. See all ACE inhibitor drugs at /class/ace-inhibitor.

What development phase is ACE inhibitors in?

ACE inhibitors is FDA-approved (marketed).

What are the side effects of ACE inhibitors?

Common side effects of ACE inhibitors include Persistent dry cough, Hyperkalemia, Dizziness, Fatigue, Angioedema, Hypotension.

What does ACE inhibitors target?

ACE inhibitors targets Angiotensin-converting enzyme (ACE) and is a ACE inhibitor.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing